HitGen Enhances Drug Discovery Through Strategic Funding
HitGen Inc. is proud to announce a new strategic funding collaboration aimed at advancing the discovery of innovative therapeutics for underserved ailments. By forging an agreement with the Gates Foundation, HitGen aims to leverage its leading DNA-encoded library (DEL) technology to develop drug leads addressing critical health issues such as tuberculosis and malaria, while also focusing on non-hormonal contraception solutions.
Collaboration with the Gates Foundation
This partnership marks a significant step in HitGen's mission to improve healthcare outcomes. Under this collaboration, HitGen will perform DEL screening on 15 specific drug targets identified by the Gates Foundation, in cooperation with esteemed academic institutions and research partners worldwide. This funding will facilitate advanced discovery initiatives, allowing HitGen to build on previous success in identifying effective drug leads for malaria and tuberculosis.
Leadership Insights
Dr. Jin Li, the Chairman and Chief Executive Officer of HitGen, expressed enthusiasm regarding the collaboration: "We are honored to continue this important work with support from the Gates Foundation. We look forward to engaging with other world-leading philanthropic and academic institutions to deliver transformative solutions for patients with unmet medical needs." These words reflect HitGen's dedication to tackling significant healthcare challenges.
Innovative Technology Platforms
HitGen stands at the forefront of drug discovery technologies. The company has harnessed the power of DEL, with access to over 1.2 trillion small molecules generated through this technology. The efficiency and success of HitGen's screening processes provide unparalleled opportunities for drug discovery across various sectors, facilitating collaborations with organizations globally.
About HitGen Inc.
HitGen Inc. (SSE: 688222.SH), operates primarily from its headquarters in Chengdu, China, while maintaining subsidiaries in Cambridge, UK, and Houston, USA. The company is renowned for its innovative platforms that foster the discovery and optimization of both small molecules and nucleic acid-based pharmaceuticals. Key technologies include world-leading DEL, fragment-based drug discovery, structure-based drug design, and emerging platforms marrying AI with molecular optimization techniques. HitGen also engages in collaborations with hundreds of biopharmaceutical entities around the globe, sustaining multiple programs from early discovery stages to clinical trials.
Frequently Asked Questions
What is the primary goal of HitGen's new funding?
The funding aims to support the discovery of new drug leads for diseases like tuberculosis and malaria, as well as agents for non-hormonal contraception.
Who is HitGen partnering with for this initiative?
HitGen is collaborating with the Gates Foundation and various academic institutions to achieve its goals.
What technology does HitGen utilize for drug discovery?
HitGen uses an advanced DNA-encoded library (DEL) platform that allows for screening vast libraries of potential drug compounds.
How does HitGen's technology benefit drug discovery?
The DEL technology enhances the efficiency of the drug discovery process, enabling quicker identification of promising drug candidates.
Where is HitGen headquartered?
HitGen is headquartered in Chengdu, China, with additional offices in the UK and the USA.
